Why the study?
Do different potent renin inhibitors (remikiren, CGP 38560A, enalkiren) have differing effects on arterial pressure in sodium-depleted normotensive squirrel monkeys?
Population
Sodium-depleted normotensive squirrel monkeys
Comparison
Remikiren, CGP 38560A, and enalkiren vs Cilazapril (ACE inhibitor) and each other
Design
Preclinical
Authors
Loading...
Remikiren's BP advantage in primates despite equivalent Ang II suppression; hypothesis-generating for extraplasmatic effects, untested in humans.
Do different potent renin inhibitors (remikiren, CGP 38560A, enalkiren) have differing effects on arterial pressure in sodium-depleted normotensive squirrel monkeys?
Remikiren demonstrates superior blood pressure reduction compared to other renin inhibitors in a primate model, suggesting potential extraplasmatic renin inhibition.
Clozel et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: